did not find progression of IIM-ILD and changes in PFTs over time in anti-TRIM21-positive patients with IIM, but found an increase in the patient’s lung diffusion capacity (DLCO) at five-year follow-up (162, 165). The gene discussed is TRIM21; the disease is acquired idiopathic inflammatory myopathy.